指南与共识肝病

AGA/AASLD 原发性胆汁性胆管炎管理临床实践指南

AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis.
指南 / 共识 · Gastroenterology · 2026-01-01

美国胃肠病协会与美国肝病研究协会组织多学科专家组,针对成人原发性胆汁性胆管炎(PBC)的6个优先临床问题完成系统评价,采用 GRADE 框架形成6条推荐,涵盖抗线粒体抗体阴性疑诊PBC的抗体检测、熊去氧胆酸(UDCA)一线治疗、肝硬度评估预后、PPAR激动剂用于UDCA应答不佳或不耐受者、linerixibat治疗中重度瘙痒及肝移植后UDCA预防复发。

要点

  • 推荐UDCA作为PBC一线治疗,并强调早期诊断与一线治疗优化。
  • 对UDCA应答不佳或不耐受者,推荐过氧化物酶体增殖物激活受体激动剂。
  • linerixibat可用于PBC相关中重度瘙痒,肝移植后可用UDCA预防复发。

核心结论

  • 指南强调早期诊断、优化一线治疗、基于风险的治疗升级、症状管理及预防肝移植后疾病复发,以改善患者结局与生活质量。

研究设计与样本

  • 美国胃肠病协会(AGA)与美国肝病研究协会(AASLD)召集多学科专家组制定成人PBC临床实践推荐。
  • 针对6个优先临床问题完成系统评价,采用 GRADE 框架评估证据并形成推荐。

主要发现

  • 专家组就6个临床问题达成6条推荐,证据确定性从中等到极低。
  • 推荐涉及抗线粒体抗体阴性疑诊PBC的PBC特异性抗核抗体检测、UDCA一线治疗及肝硬度测量用于预后评估。
  • 推荐涉及UDCA应答不佳或不耐受者使用过氧化物酶体增殖物激活受体激动剂、linerixibat治疗中重度瘙痒及肝移植后UDCA预防复发。

关键数值与推荐

  • 推荐在抗线粒体抗体阴性但疑诊PBC时检测PBC特异性抗核抗体。
  • 推荐UDCA作为PBC一线治疗。
  • 推荐采用肝硬度测量进行预后评估。
  • 推荐对UDCA应答不佳或不耐受者使用过氧化物酶体增殖物激活受体激动剂。
  • 推荐linerixibat用于中重度瘙痒,并推荐肝移植后使用UDCA预防疾病复发。

临床怎么用

  • 对疑诊PBC但抗线粒体抗体阴性者,应加测PBC特异性抗核抗体以助诊断。
  • 确诊PBC后以UDCA为一线治疗,并用肝硬度测量进行风险分层与预后评估。
  • UDCA应答不佳或不耐受者可考虑过氧化物酶体增殖物激活受体激动剂,中重度瘙痒可考虑linerixibat。
  • 肝移植后可使用UDCA预防PBC复发。

局限性

  • 证据确定性范围为中等至极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with progressive fibrosis, cirrhosis, liver transplantation, and premature mortality. Despite effective therapies, important challenges remain in the diagnosis and management of PBC, including identification of antimitochondrial antibody-negative disease, assessment of response to ursodeoxycholic acid (UDCA), risk stratification, treatment of patients with inadequate response, management of cholestatic pruritus, and prevention of recurrent disease after liver transplantation. The aim of this guideline was to develop evidence-based recommendations addressing these key areas of clinical care. METHODS: The American Gastroenterological Association (AGA) and the American Association for the Study of Liver Diseases (AASLD) convened a multidisciplinary panel to develop clinical practice recommendations for adults with PBC. Systematic reviews were performed for 6 prioritized clinical questions. The Grading of Recommendations Assessment, Development and Evaluation framework was used to prioritize clinical outcomes and assess evidence, and its Evidence to Decision Framework was used to develop recommendations. RESULTS: The guideline panel agreed on 6 recommendations. These recommendations address the use of PBC-specific antinuclear antibodies in antimitochondrial antibody-negative suspected PBC, UDCA as first-line therapy, liver stiffness measurement for prognostication, peroxisome proliferator-activated receptor agonists for patients with inadequate response or intolerance to UDCA, linerixibat for moderate to severe pruritus, and UDCA prophylaxis post-transplantation to reduce disease recurrence. The certainty of evidence ranged from moderate to very low. CONCLUSIONS: The guideline emphasizes early diagnosis, optimization of first-line therapy, risk-based treatment escalation, symptom management, and prevention of post-transplantation disease recurrence to improve patient outcomes and quality of life.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Levy, Mayo, Carey, et al. AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis. Gastroenterology. 2026. PMID: 42914292. doi:10.1053/j.gastro.2026.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。